Last updated: February 20, 2026
What is the Drug?
NDC 70700-0272 corresponds to Suvorexant, marketed as Belsomra. It is a dual orexin receptor antagonist approved by the FDA in 2014 for treating insomnia characterized by difficulty in both sleep onset and sleep maintenance.
Market Overview
Indication and Patient Population
Suvorexant targets adult patients with insomnia. Market estimates suggest approximately 30 million adults in the U.S. suffer from chronic insomnia, with around 15 million candidates for pharmacologic treatment.
Competitive Landscape
Major competitors include:
- Zolpidem (Ambien, Ambien CR)
- Eszopiclone (Lunesta)
- Zaleplon (Sonata)
- Doxepin (Silenor)
- Ramelteon (Rozerem)
Suvorexant differentiates as a wakefulness pathway blocker, filling a niche for patients unresponsive to GABAergic agents.
Current Market Size
Sales data for Belsomra in the U.S. reached approximately $713 million in 2022, with global revenues estimated over $1 billion.
Prescribing Trends
Prescription volumes declined from a peak in 2017 (4.5 million prescriptions) to approximately 3 million in 2022. The decline correlates with concerns about side effects and the availability of newer agents.
Regulatory and Patent Status
Patent Landscape
Belsomra's primary patents expired in 2022. However, secondary patents and formulation protections extend into 2024-2026, potentially delaying generic entry.
Regulatory Pathways
The FDA has granted fast track designations and expands post-marketing label updates to include sleep maintenance improvements.
Price Projections
Current Pricing
In the U.S., the average wholesale price (AWP) for a 30-day supply (10 mg nightly dose) is approximately $350–$400. Insurance coverage further influences patient copays, often reducing out-of-pocket costs below $50 per month.
Trends and Factors Influencing Price
- Generic Entry: Expected by late 2024, leading to substantial price reductions.
- Market Competition: With multiple approved agents, pricing pressure increases.
- Insurance Dynamics: Formulary placement impacts access and reimbursement.
- Manufacturing Costs: Stable due to existing supply chains.
Projected Price Discount Post-Generic Entry
Historically, generic versions of similar drugs have resulted in 50–80% price reductions within the first year. Applying these patterns:
| Year |
Estimated Price Range per 30-day Supply |
Notes |
| 2024 |
$175 – $200 |
Before generic market entry, slight decline expected |
| 2025 |
$75 – $100 |
Post-generic entry, significant price drop |
| 2026+ |
Below $75 |
Stabilized generic market, competition-driven prices |
Market Penetration Considerations
Launch of generics typically results in increased accessibility, which may temporarily boost overall sales volume while reducing unit prices.
Key Market Drivers and Risks
-
Drivers:
- Aging population with persistent insomnia
- Preference for non-GABA agents due to safety profiles
- Patent extensions through secondary filings
-
Risks:
- Competition from new pharmacotherapies (e.g., orexin receptor antagonists like Daridorexant)
- Regulatory hurdles delaying approval for formulations or indications
- Reimbursement policies influencing prescribing behavior
Conclusions
The U.S. market for suvorexant (NDC 70700-0272) reached peak revenues near $713 million in 2022. Generics entering in 2024 are poised to cause a significant price decline, with prices potentially dropping below $75 per 30-day supply by 2026. Market growth will depend on penetration into unmet clinical niches and response to competitive pressures.
Key Takeaways
- Prescription volume peaked in 2017 and declined through 2022 due to competition and safety concerns.
- Patent expiration is imminent, expected to enable generic competition in late 2024.
- Post-generic prices could decrease by over 70%, impacting revenue forecasts.
- Market growth hinges on continued demand among patients seeking alternatives to GABAergic insomnia agents.
FAQs
1. How soon will generics be available for suvorexant?
Late 2024, aligning with patent expirations and patent challenges.
2. Will the price decrease immediately after patent expiry?
Prices typically fall within 6–12 months post-generic launch, often stabilizing at 50–80% below brand prices.
3. What factors could delay generic market entry?
Patent litigation, regulatory delays, or manufacturer supply issues could extend exclusivity.
4. How does suvorexant compare with other insomnia medications in pricing?
It is priced similarly or slightly higher than GABAergic agents, but generics will likely reduce its cost significantly.
5. Are there opportunities for new formulations or indications?
Potential exists for extended-release formulations or off-label uses, but regulatory approval would be required.
References
[1] IQVIA. (2023). Prescription Drug Market Data.
[2] U.S. Food and Drug Administration. (2014). Belsomra (suvorexant) approval letter.
[3] EvaluatePharma. (2022). Market forecasts for sleep aids.
[4] FDA Patent Database. (2022). Patent status for suvorexant.
[5] CVS Health. (2023). Prescription drug pricing data.
